CODX Capital Surpluse from 2010 to 2024

CODX Stock  USD 0.94  0.01  1.08%   
Co Diagnostics Capital Surpluse yearly trend continues to be fairly stable with very little volatility. Capital Surpluse is likely to outpace its year average in 2024. During the period from 2010 to 2024, Co Diagnostics Capital Surpluse regression line of annual values had r-squared of  0.81 and arithmetic mean of  33,305,530. View All Fundamentals
 
Capital Surpluse  
First Reported
2017-06-30
Previous Quarter
90.6 M
Current Value
92.8 M
Quarterly Volatility
29 M
 
Covid
Check Co Diagnostics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Co Diagnostics' main balance sheet or income statement drivers, such as Interest Expense of 18 M, Selling General Administrative of 15 M or Total Revenue of 6.5 M, as well as many indicators such as Price To Sales Ratio of 5.44, Dividend Yield of 0.0 or PTB Ratio of 0.43. CODX financial statements analysis is a perfect complement when working with Co Diagnostics Valuation or Volatility modules.
  
Check out the analysis of Co Diagnostics Correlation against competitors.
For more information on how to buy CODX Stock please use our How to Invest in Co Diagnostics guide.

Latest Co Diagnostics' Capital Surpluse Growth Pattern

Below is the plot of the Capital Surpluse of Co Diagnostics over the last few years. It is Co Diagnostics' Capital Surpluse historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Co Diagnostics' overall financial position and show how it may be relating to other accounts over time.
Capital Surpluse10 Years Trend
Slightly volatile
   Capital Surpluse   
       Timeline  

CODX Capital Surpluse Regression Statistics

Arithmetic Mean33,305,530
Geometric Mean10,259,369
Coefficient Of Variation122.03
Mean Deviation34,659,928
Median16,260,650
Standard Deviation40,641,332
Sample Variance1651.7T
Range105.3M
R-Value0.90
Mean Square Error332.4T
R-Squared0.81
Slope8,194,623
Total Sum of Squares23124T

CODX Capital Surpluse History

2024106.8 M
2023101.7 M
202288.5 M
202180.3 M
202049.2 M
201926.7 M
201817.6 M

About Co Diagnostics Financial Statements

Co Diagnostics investors use historical fundamental indicators, such as Co Diagnostics' Capital Surpluse, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Co Diagnostics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Capital Surpluse101.7 M106.8 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for CODX Stock Analysis

When running Co Diagnostics' price analysis, check to measure Co Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Co Diagnostics is operating at the current time. Most of Co Diagnostics' value examination focuses on studying past and present price action to predict the probability of Co Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Co Diagnostics' price. Additionally, you may evaluate how the addition of Co Diagnostics to your portfolios can decrease your overall portfolio volatility.